Conversely, none of the subgroup analyses performed in high-risk patients, including those beyond particular selection criteria, with ≥3 tumours, alpha-fetoprotein concentration ≥48.3 ng/mL, or with tumours either poorly differentiated or with microvascular invasion, revealed a significant effect of IRI on the risk of HCC recurrence. The gene discussed is AFP; the disease is neoplasm.